Kinopharma

News


2017/09/28
Our project "antiviral drug development for Human
          Papillomavirus(HPV), which causes cervical cancer",
          was adopted as a grant of the KYOTO Industrial
          Support Organization 21.

2017/08/24
Mr. Kuroishi, CEO,showed the status of our business
          regarding development of the anti-virus agentat the
          "IPO Caravan" sponsored by the Mitsubishi UFJ Trust Bank.

2017/08/04
Mr. Kuroishi, CEO, had an oral presentation at the
          "1st Healthcare Venture Conference KYOTO" held
          at the Kyoto Research Park.

2017/07/01
We established the Exploratory Research Laboratory
         at the Innovation Hub Kyoto of Kyoto University.

2017/03/03
NEDO Research Fund has been granted.

2016/07/31
Investigator's clinical studies have commenced using
          Kinopharma's candidate antivirus compound
          at Kyoto University Hospital.

2016/05/01
We moved the headquarter office to Nihonbashi, Tokyo.

2016/04/08
The patent for the CNS project has been issued in the US.

2014/07/09
Our research achievements in the antivirus project has been
         published in The Journal of Clinical Investigation.

2013/03/12
Preclinical studies commenced in the antivirus project.

2008/05/07
We launch the revamped website.
  • Japanese